Caredx (CDNA) Stock
Diagnostic company for organ transplant monitoring. Here's the price, business snapshot, and what's worth knowing about Caredx in August 2026.
CareDx, Inc. (CDNA) specialises in diagnostic tests and monitoring solutions for organ transplant patients. Its portfolio includes non‑invasive assays such as donor‑derived cell‑free DNA (AlloSure) and gene‑expression tests (AlloMap) designed to detect rejection and guide post‑transplant care. The company’s model combines laboratory services, test kits and licensing, which can generate recurring revenue from ongoing patient surveillance. Key drivers include rising transplant volumes globally, greater clinician adoption of non‑invasive monitoring, and geographic expansion. Investors should weigh these opportunities against risks: reimbursement uncertainty, competitive assays, regulatory scrutiny and the need for continued clinical evidence. With a market capitalisation near $808.5m, CareDx sits in the smaller‑cap diagnostic space where growth potential comes with higher volatility. This summary is educational only and not personalised financial advice — prospective investors should review the company’s latest filings and consider their own suitability and risk tolerance.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying CareDx's stock, with a target price suggesting significant potential for growth.
Financial Health
CareDx is generating solid revenue and cash flow, while maintaining a strong profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring revenue potential
Monitoring tests can generate repeat business as patients require long‑term surveillance, offering predictable revenue per patient — though reimbursement and volumes can vary.
Innovation in monitoring
Proprietary tests like donor‑derived cell‑free DNA and gene‑expression panels aim to reduce invasive biopsies and improve care, but continued clinical validation is important.
Market expansion path
Global transplant growth and partnerships could open new markets, yet regulatory differences and payer coverage can affect uptake and timing.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
